-
In the United States, COPD is the 4th leading cause of death. Widespread public education about smoking toxicity has not decreased COPD mortality, and since 2000 the number of women who die from COPD has eclipsed men.
-
The FDA has approved a new antifungal agent for the prevention of Aspergillus and Candida infections in at-risk individuals. Posaconazole is an oral triazole, broad spectrum, antifungal chemically similar to itraconazole.
-
People who have symptoms of allergic rhinitis report more sleep complaints, including daytime sleepiness, than do those without allergic rhinitis.
-
A program of resistive exercise and treadmill walking reduced the severity of restless legs syndrome symptoms.
-
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998.
-
For hypertensives with coronary artery disease, lowering the diastolic pressure below 70-80 mm Hg appears to create increased risk of morbidity and mortality from myocardial infarction and all-cause death.
-
The ECG image used in this article was obtained from a previously healthy, middle-aged man with some atypical but new-onset chest discomfort.
-
Other than water, tea is the most often consumed beverage in the world. Animal studies and in vitro data support the potential role of green tea consumption (GTC) for reducing cardiovascular disease and cancer.
-
The FDA has approved the first product for the treatment of Hunter syndrome. Idursulfase is a purified form of iduronate-2-sulfase, a 525-amino acid glycoprotein, produced by recombinant DNA technology.
-
Treatment of Parkinson's disease with dopamine agonist medications may precipitate impulse-control disorders such as compulsive gambling, buying, and hypersexuality.